DEFA14A: Vaxart Urges Stockholders to Approve Reverse Stock Split to Avoid Nasdaq Delisting, Addresses Investor Concerns

Vaxart, Inc. is urging stockholders to vote for a reverse stock split by June 1, 2025, to regain Nasdaq compliance and avoid delisting, while addressing frequently asked questions regarding capital raises, program funding, and market speculation.

Summary

• Vaxart adjourned its Annual Meeting of Stockholders to June 2, 2025, to allow more time for stockholders to vote on a reverse stock split proposal.
• The primary reason for the reverse stock split is to regain and maintain compliance with Nasdaq's minimum bid price requirement, with a deadline of June 30, 2025.
• The Board has committed to a maximum reverse stock split ratio of 1-for-20, a reduction from the previously proposed 1-for-50, based on investor feedback.
• The Company plans to call a special meeting shortly after the reverse stock split to propose a proportional reduction in authorized shares, also based on investor feedback.
• Vaxart raised $40 million in an underwritten offering in June 2024 to extend its cash runway beyond 12 months, as its previous runway was less than six months.
• The $460.7 million BARDA Project NextGen award for the COVID-19 Phase 2b trial is a cost-reimbursable contract and is not sufficient to fund all company operations and advance other product candidates.
• The stop work order for the BARDA-funded Project NextGen award has been lifted, with disclosure made via SEC filing due to BARDA's press release review requirements.
• Vaxart is actively exploring business development opportunities and partnerships for its programs, but believes more clinical data is needed to advance discussions.
• Management asserts it communicates all material information timely through official channels and that a majority of the executive team holds Vaxart shares.
• The Company is investigating rumors of dark pool trading and naked short selling but has no confirmed proof from authorities.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the immediate threat of Nasdaq delisting and the necessity of a reverse stock split, which often signals underlying stock performance issues. While management is addressing investor concerns and advancing programs, the ongoing need for dilutive financing and the fact that a large government award isn't sufficient for full operations weigh down the sentiment. The commitment to a lower split ratio and proportional share reduction are positive responses to feedback, but they don't negate the core problem.

Positives

• Vaxart's Board committed to a lower maximum reverse stock split ratio of 1-for-20 (down from 1-for-50) based on investor feedback.
• The Company plans to propose a proportional reduction in authorized shares alongside the reverse stock split, addressing a key investor concern.
• The $40 million capital raise in June 2024 extended the cash runway to over 12 months, enabling advancement of multiple programs including norovirus, COVID-19, and flu.
• The stop work order for the BARDA-funded Project NextGen award has been lifted, allowing the COVID-19 Phase 2b trial to proceed.
• Management has invested its own money in Vaxart, with the CEO and other executives purchasing shares, indicating confidence.
• Vaxart is actively exploring business development opportunities and partnerships for its programs.
• The company's oral pill vaccine platform offers advantages like no refrigeration and no needle-stick injury risk.

Negatives

• The company faces a potential delisting from Nasdaq due to not meeting the minimum bid price requirement.
• A reverse stock split is necessary to regain Nasdaq compliance, which is often viewed negatively by investors.
• The $460.7 million BARDA award is cost-reimbursable and not sufficient to fund all Vaxart's operations and advance other product candidates, necessitating further capital raises.
• The need for a capital raise in June 2024 was due to a cash runway of less than six months.
• More data from programs like norovirus are needed to further advance discussions with potential partners, indicating partnerships are not imminent.
• The company has no assurance that an appeal to Nasdaq regarding delisting will be successful.

Risks

• Potential delisting from Nasdaq if the Company does not regain compliance with the minimum bid price requirement by June 30, 2025.
• No assurance that an appeal to a Nasdaq hearings panel regarding a delisting determination will be successful.
• Amending the reverse stock split proposal could delay the annual meeting process and prevent Vaxart from effecting the split by the Nasdaq compliance deadline.
• Forward-looking statements in the press release may turn out to be inaccurate due to known and unknown risks, uncertainties, and other factors.
• Risks and uncertainties described under Item 1A Risk Factors in the Annual Report on Form 10-K for the year ended December 31, 2024, and any subsequent Quarterly Reports on Form 10-Q.

Future Outlook

Vaxart's future outlook is focused on regaining Nasdaq compliance through a potential reverse stock split by June 30, 2025. The company aims to drive value through data readouts from its norovirus and COVID-19 programs and continues to explore business development opportunities, though further clinical data is needed to advance partnership discussions. Management believes the current share price does not reflect the full value of its oral pill vaccine platform and product candidates.

Management Comments

• "We appreciate the continued interest from our passionate and loyal stockholder base."
• "Understanding their concerns and directly addressing their most frequently asked questions, we are hopeful that this additional information will be helpful as they consider the reverse stock split proposal."
• "The Board believes it's crucial for stockholders to have more time to vote, especially considering the potential delisting from Nasdaq."
• "The Company is focused on moving its programs forward to drive additional potential value-creating catalysts including data readouts from norovirus and COVID-19, which it believes can drive investor interest."
• "The Board and Management considered it a prudent decision to raise $40 million, which enabled the Company to extend its cash runway over 12 months through this important offering."
• "We believe that our norovirus and other programs have potential with a partner, however, at this time more data from these programs are needed to further advance our discussions with potential partners."
• "Management continues to believe that the current share price does not accurately reflect the full value of its oral pill vaccine platform and product candidates."
• "Vaxart welcomes the ongoing open dialogue amongst its stockholders, but cannot comment on or confirm every rumor or speculation found on unofficial platforms."

Industry Context

Vaxart operates in the highly capital-intensive biotechnology and vaccine development industry. The need for significant equity financing, as highlighted by Vaxart's past capital raises and ongoing need for funding beyond government awards, is typical for clinical-stage biotech companies. The focus on oral vaccines positions Vaxart uniquely against traditional injectable vaccines, aligning with a broader industry trend towards more convenient and accessible drug delivery methods. The pursuit of partnerships for clinical programs is also a common strategy in biotech to share development costs and leverage larger pharmaceutical companies' resources and market reach.

Comparison to Industry Standards

• The reliance on equity financing and strategic partners for capital is standard practice for clinical-stage biotech companies, especially those developing vaccines, which require substantial investment through various clinical trial phases.
• The structure of the BARDA award as a cost-reimbursable contract with single-digit fixed fees is typical for government-funded research and development contracts in the biodefense and public health sectors, similar to agreements seen with other vaccine developers receiving government support for pandemic preparedness.
• The challenge of maintaining Nasdaq listing requirements due to low share price is a common issue for smaller, development-stage biotech companies, often leading to reverse stock splits as a compliance mechanism, as observed across the industry.
• The need for more clinical data to advance partnership discussions is a standard hurdle in biotech business development; potential partners typically require robust Phase 2 or Phase 3 data to de-risk investments in new drug candidates.

Corporate Governance

Stakeholder Impact

• Shareholders: Directly impacted by the reverse stock split proposal, potential delisting, and ongoing dilution from capital raises. The company is actively engaging with retail investors to address concerns and encourage voting.
• Employees: Continued employment and program advancement are tied to the company's financial stability and success in clinical trials. Management holds shares, aligning their interests with other shareholders.
• Customers/Patients (future): The development of oral vaccines for norovirus, COVID-19, flu, and HPV could offer a more convenient and accessible alternative to existing or future vaccines.
• Creditors/Partners: The company's financial health and ability to execute on its BARDA contract and other programs are crucial for maintaining relationships with partners and potential future collaborators.

Next Steps

• Stockholders to vote on the reverse stock split proposal by 11:59 p.m. Eastern Time on June 1, 2025.
• Annual Meeting of Stockholders scheduled for Monday, June 2, 2025.
• If Proposal No. 2 is approved, the reverse stock split ratio will be determined near the Nasdaq compliance deadline (June 30, 2025).
• The Company will call a special meeting shortly after implementing the reverse stock split to reduce the authorized shares proportionally.
• Continue moving programs forward to drive additional potential value-creating catalysts, including data readouts from norovirus and COVID-19.
• Continue exploring business development opportunities and potential partnerships.
• Continue investigating dark pool trading or naked short selling.

Key Dates

Recommendation

Keywords

Vaxart, VXRT, Reverse Stock Split, Nasdaq Compliance, Delisting Risk, Oral Vaccine, Norovirus Vaccine, COVID-19 Vaccine, BARDA Award, Project NextGen, Biotechnology, Clinical Stage, Capital Raise, Proxy Statement, Shareholder Meeting, Vaccine Development, Biotech Financing